Evidence map›Paper›PMID 31811882›Full record

ArticleJournal of hepatology2020

Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.

Francisco Averhoff, Shaun Shadaker, Amiran Gamkrelidze, Tatia Kuchuloria, Lia Gvinjilia, Vladimer Getia, David Sergeenko, Maia Butsashvili, Tengiz Tsertsvadze, Lali Sharvadze and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04411381 (Telemedicine-based Model of Care for the Management of Hepatitis C Infected Patients), which is not on this map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04411381 naunknown statusnot on this map

Telemedicine-based Model of Care for the Management of Hepatitis C Infected Patients: a Randomized Clinical Trial

TypeinterventionalSponsorUniversity of La LagunaRan2020 to 2023Enrolled136ConditionsHepatitis C, TelemedicineArmsTelemedicine
3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Clinical and demographic characteristics of participants in a hepatitis C treatment trial in rural Kentucky: How policies around treatment access may impact elimination efforts in the United States.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015-2020.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  16. Insights from a national survey in 2021 and from modelling on progress towards hepatitis C virus elimination in the country of Georgia since 2015.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Article
  17. Toward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Article
  18. Observational
  19. Article
  20. Economic evaluation of the Hepatitis C virus elimination program in the country of Georgia, 2015 to 2017.Liver international : official journal of the International Association for the Study of the Liver · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Francisco AverhoffCenters for Disease Control and Prevention, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention, Atlanta, Georgia, USA. Electronic address: fma0@cdc.gov.
Shaun ShadakerCenters for Disease Control and Prevention, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention, Atlanta, Georgia, USA.
Amiran GamkrelidzeNational Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia.
Tatia KuchuloriaTEPHINET independent contractor for Georgia Hepatitis C Elimination Program, Atlanta, Georgia, USA.
Lia GvinjiliaTEPHINET independent contractor for Georgia Hepatitis C Elimination Program, Atlanta, Georgia, USA.
Vladimer GetiaNational Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia.
David SergeenkoMinistry of IDPs from the Occupied Territories, Labour, Health, and Social Affairs of Georgia, Tbilisi, Georgia.
Maia ButsashviliHealth Research Union, Tbilisi, Georgia.
Tengiz TsertsvadzeInfectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.
Lali SharvadzeHepatology clinic HEPA, Tbilisi, Georgia.
Jaba ZarkuaHepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia.
Beth SkaggsDivision of Global Health Protection, Center for Global Health, South Caucasus Regional Office, Tbilisi, Georgia.
Muazzam NasrullahCenters for Disease Control and Prevention, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention, Atlanta, Georgia, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

BACKGROUND &

aimsGeorgia, with a high prevalence of HCV infection, launched the world's first national hepatitis C elimination program in April 2015. A key strategy is the identification, treatment, and cure of the estimated 150,000 HCV-infected people living in the country. We report on progress and key challenges from Georgia's experience.

methodsWe constructed a care cascade by analyzing linked data from the national hepatitis C screening registry and treatment databases during 2015-2018. We assessed the impact of reflex hepatitis C core antigen (HCVcAg) testing on rates of viremia testing and treatment initiation (i.e. linkage to care).

resultsAs of December 31, 2018, 1,101,530 adults (39.6% of the adult population) were screened for HCV antibody, of whom 98,430 (8.9%) tested positive. Of the individuals who tested positive, 78,484 (79.7%) received viremia testing, of whom 66,916 (85.3%) tested positive for active HCV infection. A total of 52,576 people with active HCV infection initiated treatment and 48,879 completed their course of treatment. Of the 35,035 who were tested for cure (i.e., sustained virologic response [SVR]), 34,513 (98.5%) achieved SVR. Reflex HCVcAg testing, implemented in March 2018, increased rates of monthly viremia testing by 97.5% among those who screened positive for anti-HCV, however, rates of treatment initiation decreased by 60.7% among diagnosed viremic patients.

conclusionsOver one-third of people living with HCV in Georgia have been detected and linked to care and treatment, however, identification and linkage to care of the remaining individuals with HCV infection is challenging. Novel interventions, such as reflex testing with HCVcAg, can improve rates of viremia testing, but may result in unintended consequences, such as decreased rates of treatment initiation. Linked data systems allow for regular review of the care cascade, allowing for identification of deficiencies and development of corrective actions. LAY SUMMARY: This report describes progress in Georgia's hepatitis C elimination program and highlights efforts to promote hepatitis C virus screening and treatment initiation on a national scale. Georgia has made progress towards eliminating hepatitis C, treating over 50,000 people, approximately one-third of the number infected, and achieving cure for 98.5% of those tested. However, identifying infected individuals and linking them to care remains challenging. Novel approaches to increase diagnostic testing can have unintended consequences further down the care cascade.

Indexed as

RegistriesAdolescentAdultAgedAntiviral AgentsDisease EradicationFemaleGeorgia (Republic)HepacivirusHepatitis C AntibodiesHepatitis C AntigensHepatitis C, ChronicHumansMaleMass ScreeningMiddle AgedAntiviral AgentsHepatitis C AntibodiesHepatitis C Antigensnucleocapsid protein, Hepatitis C virusRNA, ViralViral Core ProteinsGeorgiaHCVHepatitis C diagnostic testingLinkage to careReflex testingScreening

Identifiers

PMID31811882
PMCPMC7418146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.